Functional Indications:
Used to treat type 2 diabetes. 1. Monotherapy: This product is used as an auxiliary treatment for diet control and exercise to improve blood sugar control in patients with type 2 diabetes. 2. Use in combination with metformin hydrochloride: When metformin hydrochloride alone cannot effectively control blood sugar, this product can be used in combination with metformin hydrochloride to improve blood sugar control in patients with type 2 diabetes on the basis of diet and exercise. 3. Important usage restrictions: Since the effectiveness against type 1 diabetes and diabetic ketoacidosis has not been determined, this product is not intended for use in patients with type 1 diabetes or diabetic ketoacidosis.
Dosage:
Alogliptin Benzoate Tablets: 1. Recommended dosage: The recommended dosage of this product is 25 mg once a day. This product can be taken with food or separately. 2. Patients with impaired renal function: (1) Patients with mild renal impairment (creatinine clearance: CrCl≥60mL/min) do not need to adjust the dose when using this product. (2) For patients with moderate renal impairment (creatinine clearance: 30≤CrCl<60mL/min), the dosage of this product is 12.5 mg once a day. (3) For patients with severe renal impairment (creatinine clearance: 15≤CrCl<30mL/min) or end-stage renal failure (ESRD) (CrCl<15mL/min or requiring hemodialysis), the dosage of this product is 6.25mg Once a day. Dialysis time does not need to be considered when using this product. This product has not been studied in patients receiving peritoneal dialysis. (4) Since the dosage of this product needs to be adjusted according to renal function, it is recommended to evaluate renal function before starting treatment and review it regularly.
Adverse reactions:
Alogliptin Benzoate Tablets: 1. Please refer to the instructions for details of common adverse reactions in foreign clinical experience. 2. Post-marketing experience: The adverse reactions identified during the post-marketing use of this product outside the United States came from spontaneous reports from people of unknown size. Therefore, it is impossible to accurately estimate their frequency of occurrence or determine the causal relationship with the medication. Hypersensitivity reactions include anaphylaxis, angioedema, rash, urticaria, and severe cutaneous adverse reactions; elevated liver enzymes; fulminant hepatic failure and acute pancreatitis.
Medication contraindications:
Patients with a history of serious allergic reactions to alogliptin products, including patients who have developed anaphylaxis, angioedema, or severe adverse skin reactions.
Aprepitant, also known as Aprepitant and Acetaminophen, is a grayish white to pale yellow crystalline solid chemical. Its chemical name is 5-[2(R)-[1(R)-[3,5-di(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2H-1,2,4-triazol-3-one, with a molecular formula of C23H21F7N4O3, a molecular weight of 534.42700, insoluble in water, slightly soluble in acetonitrile, soluble in ethanol, and a melting point of 75~76°C. Aprepitant is mainly used clinically to prevent acute and delayed nausea and vomiting during the initial and repeated treatment of highly emetogenic anti-tumor chemotherapy.
Nalotide capsules are used to treat constipation-predominant irritable bowel syndrome (IBS-C) in adults.
Linalotide is a guanylate cyclase C (GC-C) agonist with visceral analgesic and secretory effects.
Combination medication
Reasonable drug combination can enhance efficacy or reduce adverse drug reactions. Conversely, it can lead to reduced efficacy or increased toxicity. Some abnormal reactions may also occur, interfere with treatment, and aggravate the condition. Therefore, when patients take the medicine, do not use it with other drugs privately to avoid drug interactions. If you want to use it with other drugs at the same time, please consult a doctor or pharmacist before use.
Function:
In conjunction with diet control and exercise, it is used to improve blood sugar control in adults with type 2 diabetes.
Dosage:
There is no fixed dosage for diabetic patients to use miglitol or other antidiabetic drugs. The dose of miglitol must be determined based on its efficacy and patient tolerance, but should not exceed the maximum recommended dose (100 mg, 3 times/day). Initial dose: The recommended initial dose is 25 mg, taken before meals, 3 times a day; maintenance dose: 50 mg, 3 times a day; maximum dose: 100 mg, 3 times a day. The same medicines produced by different manufacturers may have inconsistent instructions. If you find any inconsistency in the instructions before taking the medicine, please consult your doctor or pharmacist in time.
Drug contraindications:
Disabled if allergic to this product
Related dosage forms:
tablet
Netupitant Palonosetron Capsules are used in adult patients to prevent acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy. Prevent acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Netupitant Palonosetron Capsules are composed of two drugs, netupitant and palonosetron. Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK1) receptors. Palonosetron is a 5-HT3 receptor antagonist that binds strongly to the receptor. Taking this product can prevent nausea and vomiting symptoms caused by highly or moderately emetogenic chemotherapy.
Ornithine aspartate granules are an auxiliary treatment for liver disease. Clinically, they are mainly used to treat hyperammonemia caused by acute and chronic liver diseases, such as cirrhosis, fatty liver, and hepatitis. They are particularly suitable for the treatment of early consciousness disorders or neurological complications.
This product can directly participate in the ornithine cycle in liver cells, so that most of the blood ammonia taken in by liver cells is combined with ornithine, and through the urea cycle, urea is generated and finally excreted from the body in a non-toxic form.
Aspartic acid indirectly participates in the tri-anion cycle and the synthesis of nucleic acids, provides intermediates for energy metabolism, and enhances liver energy supply.
This product can activate two key enzymes in the liver's detoxification function, enhance the liver's detoxification function, rapidly reduce excessive blood ammonia, and promote the repair and regeneration of liver cells themselves, thereby effectively improving liver function and restoring the body's energy balance.
This product is used to treat peptic ulcer, reflux esophagitis, and gastrinoma; it can also be used in combination with 2 antibiotics to eradicate Helicobacter pylori and reduce the recurrence of peptic ulcer.
Known allergy to any component of this product; first three months of pregnancy; lactation is prohibited.
Patients with liver/renal insufficiency should use this product with caution. ... Details
Pantoprazole sodium comprehensive interpretation
Effects:
This product is used to treat peptic ulcer, reflux esophagitis, and gastrinoma; it can also be used in combination with 2 antibiotics to eradicate Helicobacter pylori and reduce the recurrence of peptic ulcer.
Usage and dosage:
Oral adult common dosage: General usage: 40 mg once a day, duodenal ulcer generally takes 2 to 4 weeks, gastric ulcer and reflux esophagitis take 4 to 8 weeks. Treatment of Helicobacter pylori infection: 40 mg once a day, and combined with 2 antibiotics for treatment, the course of treatment is 1 to 2 weeks. Dosage for renal insufficiency: should not exceed 40 mg per day. Dosage for hepatic insufficiency: patients with severe liver failure should reduce to 40 mg every other day. Dosage for the elderly: should not exceed 40 mg per day, but in the treatment of Helicobacter pylori eradication, elderly patients can also use the conventional dose in the 1-week therapy, that is, 40 mg once, twice a day. The recommended dose for intravenous injection or drip is once a day, 40 mg once, and the course of treatment can be controlled according to clinical needs, but usually not more than 8 weeks. Inject 10ml of 0.9% sodium chloride injection into a vial containing pantoprazole dry material to make a stand-by solution. This solution can be directly injected intravenously (for at least 2 minutes), or mixed with 100ml of 0.9% sodium chloride injection and then dripped intravenously (for 15 to 30 minutes). It is not suitable to prepare with liquids other than the above, and the pH value of the prepared solution is 9. The prepared solution must be used within 3 hours. The same drugs produced by different manufacturers may have inconsistent instructions. If you find that the contents of the drug instructions are inconsistent before taking the medicine, please consult a doctor or pharmacist in time.
Contraindications:
Contraindicated if allergic to this product; contraindicated during pregnancy; contraindicated during lactation; use with caution if liver or kidney dysfunction occurs
Related dosage forms:
Tablets, capsules, injections
Function:
It is used to treat duodenal ulcer, gastric ulcer, reflux esophagitis, Zollinger-Ellison syndrome and other high gastric acid secretion diseases. For the treatment of duodenal ulcers complicated by Helicobacter pylori (Hp) infection. For the treatment of non-ulcer dyspepsia. Intravenous administration can be used to treat peptic ulcer bleeding, diffuse gastric mucosal lesion bleeding, anastomotic ulcer bleeding, and prevent rebleeding after gastric surgery. Intravenous administration can be used to treat acute gastric mucosal damage complicated by stress and acute gastric mucosal damage caused by aspirin.
Dosage:
For hyperacidity and prevention of stress ulcers, take 150 mg orally twice a day in the early morning and before going to bed. For duodenal ulcer, gastric ulcer, reflux esophagitis and other high gastric acid secretion diseases, take 150 mg orally twice a day; or 300 mg once a day before going to bed. For maintenance use, take 150 mg once a day before going to bed. For Zollinger-Ellison syndrome, take 600-1200 mg orally once a day. Intravenous infusion for upper gastrointestinal bleeding, small-volume injection or powder injection 50 mg once, twice a day or once every 6-8 hours, slow intravenous infusion for 1-2 hours; large-volume injection 100 mg once, 2 times a day times, slow intravenous infusion. Intravenous injection, 50 mg once, twice a day or once every 6-8 hours, slow (more than 10 minutes) intravenous injection. Intramuscular injection, 50 mg once, twice a day or once every 6-8 hours. To prevent gastric reflux and aspiration pneumonia after general anesthesia or major surgery, intravenous infusion, 50-100 mg once, diluted with 200 ml of 5% glucose injection, slow intravenous infusion 1-2 times 60-90 minutes before general anesthesia or major surgery Hour. Intravenous injection, 50-100mg once, slowly intravenously 60-90 minutes before general anesthesia or major surgery. Renal insufficiency: Patients with severe renal insufficiency should reduce the dose and monitor their plasma concentration. When used for duodenal ulcer, gastric ulcer, reflux esophagitis and other high gastric acid secretion diseases, the dose for patients with severe kidney disease is reduced to 75 mg once, twice a day. Hepatic insufficiency Patients with severe hepatic insufficiency should reduce the dose and monitor their plasma concentration. For children with upper gastrointestinal bleeding and to prevent acid reflux and aspiration pneumonia after general anesthesia or major surgery (children 8 years old and above), intravenous infusion, 2-4 mg/kg once, continuous infusion for 24 hours. Intravenous injection, 1-2mg/kg once, once every 8-12 hours.
Adverse reactions:
Cardiovascular system: tachycardia, bradycardia, asystole, atrioventricular block, ventricular premature beats, vasculitis. Metabolic/endocrine system: gynecomastia, galactorrhea. Musculoskeletal system: arthralgia, myalgia. Genitourinary system: impotence, decreased libido, acute interstitial nephritis, increased serum creatinine. Immune system: Hypersensitivity reactions (eg, bronchospasm, fever, rash, eosinophilia), allergic reactions, angioedema. Nervous system: headache, dizziness, vertigo, insomnia, drowsiness, reversible involuntary movement disorder. People with liver insufficiency may occasionally experience disorientation after taking the drug. Mental: Reversible confusion, agitation, depression, hallucinations. People with liver insufficiency may occasionally experience anxiety after taking the drug. Liver: elevated aminotransferase, hepatocellular hepatitis (with or without jaundice), cholestatic hepatitis (with or without jaundice), mixed hepatitis (with or without jaundice), liver failure. Gastrointestinal: Nausea, constipation, vomiting, diarrhea, abdominal discomfort, pain, pancreatitis. Blood: leukopenia, granulocytopenia, thrombocytopenia, agranulocytosis, pancytopenia (sometimes accompanied by bone marrow hypoplasia), aplastic anemia, acquired immune hemolytic anemia. Skin: Rash, erythema multiforme, alopecia. Eyes: Reversible blurred vision (suggesting changes in accommodation function). Others: discomfort, fatigue, local reactions to intravenous injection (burning sensation, itching). Once an adverse reaction (side effect) occurs, the medication should be stopped immediately and the doctor should be notified so that the doctor can judge the severity of the adverse reaction and take necessary measures.
Drug contraindications:
Contraindicated in children if allergic to this product Contraindicated in pregnancy Contraindicated in lactation Contraindicated in patients with liver and kidney dysfunction Use with caution
اسم الدواء]:
أغالسيداز β للحقن
[رقم الموافقة]:
S20190040
[مكونات]:
العنصر النشط هو agalsidase β. الاسم الكيميائي: α-galactosidase A البشري المؤتلف، والمشار إليه باسم rhαGAL. الصيغة الجزيئية (على أساس تسلسل الأحماض الأمينية): C2029H3080N5440587S27 Agalsidase β عبارة عن α-galactosidase A البشري المؤتلف، وتسلسل الأحماض الأمينية الخاص به هو نفس الإنزيم الطبيعي. agalsidase β المنقى هو بروتين سكري متماثل يبلغ وزنه الجزيئي حوالي 100 كيلو دالتون. يتكون البروتين الناضج من وحدتين فرعيتين من 398 حمض أميني (حوالي 51 كيلو دالتون)، تحتوي كل منها على 3 مواقع ارتباط بالجليكوزيل N. سواغ: مانيتول، مونوهيدرات فوسفات هيدروجين الصوديوم، سباعي هيدرات فوسفات هيدروجين الصوديوم.
[ملكيات]:
كتلة أو مسحوق أبيض أو أبيض مصفر مجفف بالتجميد.
يجب استخدام هذا المنتج تحت إشراف طبيب لديه خبرة في إدارة المرضى الذين يعانون من مرض فابري أو غيره من الأمراض الأيضية الوراثية.
الجرعة
الجرعة الموصى بها من هذا المنتج هي 1 ملغم/كغم، تدار عن طريق التسريب في الوريد مرة واحدة كل أسبوعين.
يجب ألا يتجاوز معدل التسريب الأولي 0.25 مجم/دقيقة (15 مجم/ساعة) لتقليل حدوث التفاعلات المرتبطة بالتسريب....
نظرًا لأن agalsidase beta (r-hagal) عبارة عن بروتين مؤتلف، فمن المتوقع أن تظهر الأجسام المضادة IgG في المرضى الذين يعانون من انخفاض نشاط الإنزيم المتبقي أو عدم وجوده على الإطلاق. يطور معظم المرضى عمومًا أجسامًا مضادة IgG لـ r-haGAL خلال 3 أشهر بعد التسريب الأول من بيتا agalsidase للحقن. مع مرور الوقت، معظم التفاعلات المصلية في التجارب السريرية....